On November 9, 2026, the FDA ordered every company that sells a GLP-1 drug to add a new warning to its label: a possible increased risk of NAION, a rare eye condition that can cause sudden and sometimes permanent vision loss. The order covers Ozempic, Wegovy, Mounjaro, Zepbound and every other GLP-1 on the market.... Continue Reading
Illinois Medicaid paid for 993,119 prescriptions for nine leading GLP-1 drugs between 2022 and 2025, at a gross cost of $1.1 billion. Every one was filled before November 9, 2026, when the FDA ordered manufacturers to add a warning about a rare form of permanent vision loss called NAION. Ankin Law analyzed four years of... Continue Reading
Stories are matched on the docket number and on NAION, non-arteritic anterior ischemic optic neuropathy, with a litigation word in the same story for product names.